NutriBand Inc. (NTRB) stock
NTRBNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends January 31
Financials through Q2 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 4, 2026Score 4/30239% above fair value
$5.59−0.22 (-3.79%)
Close on Nov 17, 2026Market cap $67.95MP/E –Yield –
NutriBand r&d expenses
Research and development expenses are spending on new products and technology.
NutriBand's R&D Expenses for the twelve months ending Jul 31, 2026 was $1.21M, down 53.6% year over year. For fiscal 2026 it was $1.89M, down 39.4% from the year before. The highest annual figure on record is $3.12M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $1.89M | -39.4% |
| FY2025 | Jan 31, 2025 | $3.12M | +59.1% |
| FY2024 | Jan 31, 2024 | $1.96M | +99.6% |
| FY2023 | Jan 31, 2023 | $982.23K | +138.8% |
| FY2022 | Jan 31, 2022 | $411.38K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ2 2026 | Jul 31, 2026 | $322.19K | -42.7% |
| Q1 FY2027CQ1 2026 | Apr 30, 2026 | $247.26K | -63.8% |
| Q4 FY2026CQ4 2025 | Jan 31, 2026 | $188.04K | -61.6% |
| Q3 FY2026CQ3 2025 | Oct 31, 2025 | $457.11K | -48.1% |
| Q2 FY2026CQ2 2025 | Jul 31, 2025 | $562.55K | -27.3% |
| Q1 FY2026CQ1 2025 | Apr 30, 2025 | $683.43K | -29.9% |
| Q4 FY2025CQ4 2024 | Jan 31, 2025 | $489.86K | -13.0% |
| Q3 FY2025CQ3 2024 | Oct 31, 2024 | $880.77K | +59.7% |
| Q2 FY2025CQ2 2024 | Jul 31, 2024 | $773.98K | +73.9% |
| Q1 FY2025CQ1 2024 | Apr 30, 2024 | $974.54K | +143.4% |
| Q4 FY2024CQ4 2023 | Jan 31, 2024 | $563.37K | +90.4% |
| Q3 FY2024CQ3 2023 | Oct 31, 2023 | $551.50K | +89.7% |
| Q2 FY2024CQ2 2023 | Jul 31, 2023 | $445.12K | +60.2% |
| Q1 FY2024CQ1 2023 | Apr 30, 2023 | $400.43K | +239.9% |
| Q4 FY2023CQ4 2022 | Jan 31, 2023 | $295.83K | +18.1% |
| Q3 FY2023CQ3 2022 | Oct 31, 2022 | $290.72K | – |
| Q2 FY2023CQ2 2022 | Jul 31, 2022 | $277.87K | – |
| Q1 FY2023CQ1 2022 | Apr 30, 2022 | $117.81K | – |
| Q4 FY2022CQ4 2021 | Jan 31, 2022 | $250.38K | – |
See a number that looks wrong?